Diagnostic and Prognostic Markers of Endometriosis in Menstrual Blood
- Disease/Condition
- Endometriosis
- Study type
- Observational
- Primary sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Location
- Paris, France
- Phase
- N/A
- Start date
- Mar 01, 2024
- End date
- Oct 01, 2027
- Enrollment
- 250 participants
Diagnostic and prognostic score
The goal of this observational study is to identify diagnostic and prognostic biomarkers for
 endometriosis using menstrual blood, an easily accessible yet overlooked biological fluid in
 women of reproductive age, affected or not by endometriosis
 
 The main questions it aims to answer are:
 
 - are there relevant differences in the menstrual blood of women affected by endometriosis
 compared to women without endometriosis?
 
 - do some of these differences disappear or lessen when the disease is treated by surgery?
 Participants will answer questions relevant to endometriosis and provide menstrual blood
 1 to 3 times (self-collected with a menstrual cup). A subgroup of participants affected
 by endometriosis that will undergo surgery for their regular care will provide menstrual
 blood before and after their surgery.
 
 Researchers will compare the menstrual blood of women with and without endometriosis, and
 before and after surgery to see if they can identify significant differences.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06245512
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06245512 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut National de la Santé Et de la Recherche Médicale, France and is currently Not yet recruiting. The study focuses on Endometriosis. Target enrollment is 250 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.